These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19902377)

  • 21. Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE.
    Grossfeld GD; Latini DM; Lubeck DP; Broering JM; Li YP; Mehta SS; Carroll PR
    Urology; 2002 Apr; 59(4):560-5. PubMed ID: 11927314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer.
    Ou YC; Chen JT; Yang CR; Cheng CL; Ho HC; Kao YL; Ko JL; Hsieh YS
    Jpn J Clin Oncol; 2002 May; 32(5):172-6. PubMed ID: 12110644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors.
    Jack GS; Cookson MS; Coffey CS; Vader V; Roberts RL; Chang SS; Smith JA; Shappell SB
    J Urol; 2002 Aug; 168(2):519-24. PubMed ID: 12131301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer.
    Narayan P; Gajendran V; Taylor SP; Tewari A; Presti JC; Leidich R; Lo R; Palmer K; Shinohara K; Spaulding JT
    Urology; 1995 Aug; 46(2):205-12. PubMed ID: 7542823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.
    Krumholtz JS; Carvalhal GF; Ramos CG; Smith DS; Thorson P; Yan Y; Humphrey PA; Roehl KA; Catalona WJ
    Urology; 2002 Sep; 60(3):469-73; discussion 473-4. PubMed ID: 12350486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Definitive pathology at radical prostatectomy is commonly favorable in men following initial active surveillance.
    Hong SK; Sternberg IA; Keren Paz GE; Kim PH; Touijer KA; Scardino PT; Eastham JA
    Eur Urol; 2014 Aug; 66(2):214-9. PubMed ID: 23954083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.
    King CR; McNeal JE; Gill H; Presti JC
    Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):386-91. PubMed ID: 15145152
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does extended prostate needle biopsy improve the concordance of Gleason scores between biopsy and prostatectomy in the Taiwanese population?
    Yang CW; Lin TP; Huang YH; Chung HJ; Kuo JY; Huang WJ; Wu HH; Chang YH; Lin AT; Chen KK
    J Chin Med Assoc; 2012 Mar; 75(3):97-101. PubMed ID: 22440266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing the number of biopsies increases the concordance of Gleason scores of needle biopsies and prostatectomy specimens.
    Divrik RT; Eroglu A; Sahin A; Zorlu F; Ozen H
    Urol Oncol; 2007; 25(5):376-82. PubMed ID: 17826653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database.
    Freedland SJ; Presti JC; Terris MK; Kane CJ; Aronson WJ; Dorey F; Amling CL;
    J Urol; 2003 Jun; 169(6):2129-35. PubMed ID: 12771734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gleason scores of prostate biopsy and radical prostatectomy specimens over the past 10 years: is there evidence for systematic upgrading?
    Smith EB; Frierson HF; Mills SE; Boyd JC; Theodorescu D
    Cancer; 2002 Apr; 94(8):2282-7. PubMed ID: 12001128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biopsy criteria for determining appropriateness for active surveillance in the modern era.
    Kryvenko ON; Carter HB; Trock BJ; Epstein JI
    Urology; 2014 Apr; 83(4):869-74. PubMed ID: 24680457
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy.
    Amin A; Partin A; Epstein JI
    J Urol; 2011 Oct; 186(4):1286-90. PubMed ID: 21862072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contemporary Epstein Criteria with Biopsy-Naïve Multiparametric Magnetic Resonance Imaging to Prevent Incorrect Assignment to Active Surveillance in the PI-RADS Version 2.0 Era.
    Fan Y; Zhai L; Meng Y; Chen Y; Sun S; Wang H; Hu S; Shen Q; Liu Y; Li D; Feng X; He Q; Wang X; Yu W; Jin J
    Ann Surg Oncol; 2018 Nov; 25(12):3510-3517. PubMed ID: 30225837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features.
    Boccon-Gibod LM; Dumonceau O; Toublanc M; Ravery V; Boccon-Gibod LA
    Eur Urol; 2005 Dec; 48(6):895-9. PubMed ID: 16125298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of outcome after radical prostatectomy in men with organ-confined Gleason score 8 to 10 adenocarcinoma.
    Rioux-Leclercq NC; Chan DY; Epstein JI
    Urology; 2002 Oct; 60(4):666-9. PubMed ID: 12385930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual prostatic tumour in the surgical bed following radical prostatectomy in organ-confined prostate cancer: possible prognostic significance.
    Valotto C; Falconieri G; Pizzolitto S; Cerruto MA; Brondani G; De Gobbi A; Zattoni F
    Arch Ital Urol Androl; 2011 Jun; 83(2):78-82. PubMed ID: 21826879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.